MACROGENICS, INC. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
MACROGENICS, INC. (MGNX) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $2.04 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2022-02-24
- MACROGENICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2021 was $2.04M.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month |
|---|---|
| 2021-12-31 | $2.04M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |